Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$559.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph G. Oliveto
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Beta
- 0.98
- Country
- CA
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -3.66
Financials
Revenue
$559.0K-96.3%Net Income
$-28.61MEBITDA
$-23.83MFree Cash Flow
$-22.56MEPS (diluted)
$-0.21Shares Outstanding (diluted)
138.69M+486.5%Operating Expenses
$26.16MCash & Debt
$170.61MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.55M | $-63.06M | $-0.75 |
| 2024 | $0.00 | $-41.52M | $-0.67 |
| 2023 | $1.00M | $-59.69M | $-1.39 |
| 2022 | $5.00M | $-58.39M | $-1.35 |
| 2021 | $15.00M | $-42.85M | $-1.02 |
| 2020 | $0.00 | $-49.97M | $-1.70 |
| 2019 | $0.00 | $-55.23M | $-3.50 |
| 2018 | $0.00 | $-23.18M | $-0.98 |
| 2017 | $0.00 | $-8.09M | $-0.34 |
Valuation
MISThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-54.84%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·12d ago·Positive
…Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atr…
View source ↗ - Newsglobenewswire.com·33d ago·Positive
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences.
View source ↗ - Newsglobenewswire.com·40d ago·Positive
…n Patients' Daily Lives and Quality of Life Between Episodes MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives and quality of life in the periods between episodes.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
View source ↗ - Newsseekingalpha.com·49d ago·Negative
…ing Sell As The Losses Compound Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial uptake versus low-cost generics. MIST's Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage, with only ~20% of the PSVT market covered. Financial health is deteriorating: $170M cash, $39M 1H burn, liabilities doubled to $163M, and equity fell to $18M amid high SG&A and compounding royalty debt.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Positive
Milestone Pharmaceuticals Q2 Earnings Call Highlights Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.
View source ↗ - Newszacks.com·55d ago·Negative
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise -11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.21 vs $-0.20miss
- Wed, May 13$-0.20 vs $0.06miss
- Fri, Mar 20$-0.16 vs $-0.18beat
- Wed, Nov 12$-0.12 vs $-0.17beat
- Tue, Aug 12$-0.20 vs $-0.18miss
- Wed, May 14$-0.31 vs $-0.19miss
Estimates and results for MIST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MIST officers and directors.
- Bought
- —
- Sold
- $1.2m
0 trades
13 trades
- Oliveto Josephsold
- Bharucha Davidsold
- Nelson Jeffrey Edwardsold
- Muller Lorenzsold
- Hasija Amitsold
- Oliveto Josephsold
- Oliveto Josephsold
- Oliveto Josephsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MIST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.